Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.